We are the next frontier for investment.
Next health unicorn: loading.
Investment Ask
Seed Round
Math Biology has officially closed its Round 1, and we’re just getting started.
Backed by a strong coalition of holdings, entrepreneurs and business angels who believe in our mission to revolutionize diagnostics through non-invasive, systems-level biology.
FUNDING REQUIREMENTS
$13M Target (SAFE / Equity)
$48M Pre-money valuation
CAPITAL
SECURED
$2.37M Raised so far
FUNDS ALLOCATION
40% Marketing & Science
25% Team
35% Tech & Clinical
the next frontier for investment
DMA® technology is a revolutionary, low-risk investment aligned with global healthcare trends. It fosters cross-disciplinary collaboration, offers a scalable and sustainable business model, and delivers real clinical, social, and industrial benefits. It’s poised to become the next healthcare unicorn.
DMA® is a non-invasive, zero-waste technology delivering maximum effectiveness with minimal risk, backed by real-world data.
Delivers comprehensive metabolic profiles for more accurate diagnoses and targeted therapies.
Enables high-quality screening anywhere—ideal for underserved areas—promoting equity in access to care.
Math Biology is ready for global expansion, with a business model designed for adoption in both developed and emerging markets.
Reduces invasive testing and healthcare costs through earlier diagnoses, supporting the sustainability of public health systems.
Opens new frontiers in research and medicine, accelerating the development of more effective treatments.
Drives the creation of new wellness devices and services, unlocking revenue streams for insurers and pharma alike.
Easily integrates with existing healthcare solutions, creating synergies and strategic partnership opportunities.
DMA® enables a systemic view of the human body, improving the precision and quality of care.
100,000 individual
assessments within
the first year
after investment
We are creating one of the largest regulatory-grade bioelectrical–metabolic datasets globally.
Clinical trials on the most critical conditions, in collaboration with research hospitals:
